Indeed, a phase I clinical trial is underway in ovarian cancer patients testing repeated intraperitoneal administration of autologous MV-NIS–infected adipose-derived MSC (ClinicalTrials.gov identifier: NCT 02068794). The gene discussed is SLC5A5; the disease is ovarian cancer.